Results 121 to 130 of about 28,601 (275)

Corticocortical evoked potential amplitude is altered by cortical stimulation in epilepsy

Epilepsia, EarlyView.
Abstract Objective Neurostimulation is an established therapy for drug‐resistant epilepsy, but optimizing stimulation parameters remains a major challenge. Corticocortical evoked potential (CCEP) amplitude may serve as an immediate biomarker of neurostimulation effects, enabling rapid parameter optimization.
Bethany J. Stieve, Aaron F. Struck, Dillon Scott, Richard Chappell, Andrew T. Knox   +4 more
wiley   +1 more source

Long-term efficacy of levetiracetam for partial seizures

, 2005
SummaryObjectiveTo obtain descriptive safety and efficacy data for long-term levetiracetam therapy and to allow patients benefiting from add-on levetiracetam to continue treatment until the drug was available commercially.MethodsThis long-term ...
Schaich, Lynn, Bassel Abou-Khalil, Abou-Khalil, Bassel, Lynn Schaich   +3 more
core   +1 more source

Low diagnostic yield of presurgical genetic testing in adult patients with epilepsy

Epilepsia, EarlyView.
Abstract Objective To determine the diagnostic yield of genetic testing in patients undergoing presurgical evaluation for epilepsy. Methods We conducted a cohort study including 115 adult patients who underwent presurgical evaluation in the Calgary Epilepsy Program between 2019 and 2023 and who had undergone research exome sequencing.
Clara Jünemann, Amanda Stuart, Navprabhjot Kaur, Samuel Wiebe, Nathalie Jette, Shaily Singh, Felippe Borlot, Susanne Knake, The Calgary Comprehensive Epilepsy Program Collaborators, Paolo Federico, Colin Josephson, William Murphy, Andrea Salmon, Guillermo Delgado Garcia, Walter Hader, Ping Yee Billie Au, Karl Martin Klein   +16 more
wiley   +1 more source

Seizure relapse in new onset epilepsy: It is not always drug resistance

Epilepsia, EarlyView.
Abstract Objective Seizure recurrence in new onset epilepsy (NOE) can result from various factors. Although drug ineffectiveness is frequently investigated, other causes—such as nonadherence, inadequate treatment, nonepileptic events (e.g., functional/dissociative), or acute symptomatic seizures—also impact patient outcomes.
Cecilia Catania, Eric Menetre, Aikaterini Fitsiori, Felix Tobias Kurz, Gabriela Moreno Legast, Serge Vulliemoz, Mathieu Genoud, Pierre Mégevand, Roland Wiest, Fabienne Picard, Sandor Beniczky, Margitta Seeck   +11 more
wiley   +1 more source

Clinical validation of a patient‐friendly saliva microsampling approach to monitor perampanel levels in people with epilepsy

Epilepsia, EarlyView.
Abstract Perampanel (PER) is a third‐generation antiseizure medication (ASM) with a well‐established concentration–effect relationship. Saliva represents a non‐invasive alternative to plasma for therapeutic drug monitoring (TDM) of PER, as it reflects the free plasma fraction.
Valentina Franco, Francesca Dattrino, Michela Palmisani, Federica Tacchella, Elena Tartara, Valentina De Giorgis, Carlo Alberto Quaranta, Ludovica Pasca, Paola Rota, Emilio Russo, Andrea Romigi, Cecilie Johannessen Landmark, Guido Fedele, Cristina Tassorelli, Pierluigi Nicotera   +14 more
wiley   +1 more source

Long‐term prognosis of pharmacotherapy in newly diagnosed focal epilepsy patients and the predictive value of baseline seizure timing: A prospective cohort study

Epilepsia, EarlyView.
Abstract Objective Epilepsy is a highly heterogeneous neurological disorder with significant prognostic variability. Accurate long‐term outcome prediction remains a clinical challenge. We investigated pharmacotherapeutic prognosis and key predictors, particularly baseline seizure timing, to guide individualized treatment.
Lei Sun, Shouye Sun, Xinyue Zhang, Weihong Lin   +3 more
wiley   +1 more source

Pharmacokinetics of Levetiracetam in Neonates with Seizures

, 2011
Neonatal seizures are a common problem in the first month of life. Phenobarbital is still the most frequently used medication to treat neonatal seizures,1 despite evidence that it causes neuronal apoptosis in animal models2 and may have long-term adverse
Sherwin, Catherine M.T., Stephanie L. Merhar, Meinzen-Derr, Jareen, Balmakund, Tonya, Schibler, Kurt R., Kurt R. Schibler, Jareen Meinzen-Derr, Merhar, Stephanie L., Alexander A. Vinks, Shi, Jing, Tonya Balmakund, Jing Shi, Vinks, Alexander A., Catherine M. Sherwin   +13 more
core   +1 more source

Add‐on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss‐of‐function γ‐aminobutyric acid type A receptor variants

Epilepsia, EarlyView.
Abstract Objective The semisynthetic compound vinpocetine has gained attention as a potential precision medicine for developmental and epileptic encephalopathies caused by loss‐of‐function (LoF) variants in γ‐aminobutyric acid type A (GABAA) receptor genes. As a positive allosteric modulator of GABAA receptors, case reports suggest that vinpocetine can
Cathrine E. Gjerulfsen, Vivian W. Y. Liao, Tomasz S. Mieszczanek, Anne V. Jakobsen, Elena Gardella, Kern Olofsson, Marina Nikanorova, Allan Bayat, Sebastian Ortiz, Sarah Weckhuysen, Cecilie Johannessen Landmark, Orrin Devinsky, Mary Chebib, Philip K. Ahring, Guido Rubboli, Rikke S. Møller   +15 more
wiley   +1 more source

Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy

Epilepsia, EarlyView.
Abstract Objective In patients with drug‐resistant epilepsy who undergo anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS), efficacy is assessed months after therapy initiation and clinicians have no guidance when choosing stimulation parameters due to the lack of real‐time biomarkers.
Zachary T. Sanger, Xinbing Zhang, Thomas Lisko, Hafsa Farooqi, Steffen Ventz, Sandipan Pati, Thomas R. Henry, David P. Darrow, Michael C. Park, Theoden I. Netoff, Robert A. McGovern   +10 more
wiley   +1 more source

Levetiracetam influences downstream protein interactions at synapses expressing SV2A [PDF]

, 2019
Although levetiracetam is one of the most widely prescribed antiepileptic drugs, its mechanism of action remains unknown beyond the binding to the synaptic vesicle protein SV2A. SV2A is one of the three paralogs of the SV2 family.
MARCOTULLI, DANIELE
core